In this Webcast, Karl Siegling discusses the company’s performance for the September 2018 quarter, including a more detailed review of two current positions in the portfolio, ARQ Group (ASX:ARQ) and Teva Pharmaceutical Industries (NYSE:TEVA). He then concludes with an updated outlook for the fund, and a brief overview of the upcoming Cadence Opportunities Fund […]
In this Webcast, Karl Siegling discusses the company’s expected record profit for 2018, stocks that performed well for the year and details of the final dividend. He briefly discusses global growth, the company’s outlook over the coming year and then concludes by introducing the upcoming Initial Public Offering (IPO) – Cadence Opportunities Fund.
In this video Karl discusses the company’s upcoming LIC and the following key points: Details of the new listing and how it differs from their existing Fund The investment mandate and reasons behind the shorter-term focus of the new product The structure of the upcoming offer Karl’s future role
In this Webcast, Karl Siegling discusses the company’s quarterly performance detailing the stocks that have performed well for the company during this period. He then discusses two stocks in the portfolio, Shine Corporation (ASX:SHJ) and Noni B (ASX:NBL), and gives an update on the company’s outlook. He closes by discussing the launch of a new […]
In this interview with InvestSMART Karl discusses the Cadence approach of only buying a stock that is fundamentally cheap and technically strong. Known for its scale-in, scale-out strategy, Cadence enters portfolio positions incrementally.
In this interview with Sky News Business Karl discusses the withdrawal of the major banks from areas seen as higher risk lending, for example ‘non-conforming loans’, in the wake of increased regulation from APRA and Basel. As well as the scrutiny from the Royal Commission and the significant opportunities this has created for smaller financiers […]